Shopping Cart 0
Cart Subtotal
AED 0

Uterine Leiomyoma (Uterine Fibroids)-Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22020
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Uterine Leiomyoma (Uterine Fibroids)-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uterine Leiomyoma (Uterine Fibroids)-Pipeline Review, H2 2018, provides an overview of the Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline landscape.

Uterine fibroids are benign tumors that originate in the uterus (womb). Although they are composed of the same smooth muscle fibers as the uterine wall (myometrium), they are much denser than normal myometrium. Uterine fibroids are usually round. The most common symptoms of uterine fibroids include heavy menstrual bleeding, prolonged menstrual periods seven days or more of menstrual bleeding, pelvic pressure or pain, frequent urination, difficulty emptying bladder, constipation and backache or leg pains.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uterine Leiomyoma (Uterine Fibroids)-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide also reviews of key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 3, 2, 4 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).

- The pipeline guide reviews pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Uterine Leiomyoma (Uterine Fibroids)-Overview

Uterine Leiomyoma (Uterine Fibroids)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Uterine Leiomyoma (Uterine Fibroids)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Uterine Leiomyoma (Uterine Fibroids)-Companies Involved in Therapeutics Development

AbbVie Inc

Addex Therapeutics Ltd

Auritec Pharmaceuticals Inc

Bayer AG

BioSpecifics Technologies Corp

GeneScience Pharmaceuticals Co Ltd

Immunitor Inc

Kissei Pharmaceutical Co Ltd

Luye Pharma Group Ltd

Ogeda SA

Repros Therapeutics Inc

Richter Gedeon Nyrt

Takeda Pharmaceutical Co Ltd

Uterine Leiomyoma (Uterine Fibroids)-Drug Profiles

cetrorelix-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

collagenase clostridium histolyticum-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTX-30916-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Activate Progesterone Receptor for Uterine Fibroids-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EC-313-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elagolix sodium-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fezolinetant-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KLH-2109-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leuprolide acetate SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

relugolix-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

telapristone acetate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

triptorelin acetate ER-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ulipristal acetate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

V-Myoma-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vilaprisan-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPE-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Uterine Leiomyoma (Uterine Fibroids)-Dormant Projects

Uterine Leiomyoma (Uterine Fibroids)-Discontinued Products

Uterine Leiomyoma (Uterine Fibroids)-Product Development Milestones

Featured News & Press Releases

Jul 10, 2018: Myovant Sciences Announces Completion of Screening for Phase 3 LIBERTY 1 Study Evaluating Relugolix in Women with Uterine Fibroids

Jun 29, 2018: CHMP granted a positive opinion for Ulipristal Acetate Gedeon Richter

May 18, 2018: PRAC recommends new measures to minimise risk of rare but serious liver injury with Esmya for fibroids

Apr 27, 2018: AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting

Apr 26, 2018: Allergan to Present New Data at the American College of Obstetrics and Gynecology 67th Annual Clinical and Scientific Meeting 2018

Apr 23, 2018: ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs with its Novel Oral GnRH Receptor Antagonist OBE2109 (KLH-2109)

Mar 15, 2018: Health Canada to conduct review of a new potential safety risk of Fibristal (ulipristal acetate), a medication used to treat fibroids

Mar 13, 2018: AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids

Mar 12, 2018: BioSpecifics Technologies Announces Presentation of Interim Data from Phase 1 Study of CCH for the Treatment of Uterine Fibroids at 65th Annual Scientific Meeting of the Society for Reproductive Investigation

Feb 28, 2018: Allergan Announces FDA Has Extended The Ulipristal Acetate NDA Review Period To August 2018

Feb 21, 2018: AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids

Feb 16, 2018: Esmya: no new treatment courses prescribed until further notice

Feb 09, 2018: Women taking Esmya for uterine fibroids to have regular liver tests while EMA review is ongoing

Dec 01, 2017: EMA starts review of Esmya for uterine fibroids

Nov 09, 2017: Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 Study Evaluating the Efficacy and Safety of Relugolix for the Treatment of Pain Associated with Uterine Fibroids

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by AbbVie Inc, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Addex Therapeutics Ltd, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Auritec Pharmaceuticals Inc, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Bayer AG, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by BioSpecifics Technologies Corp, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Immunitor Inc, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Kissei Pharmaceutical Co Ltd, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Luye Pharma Group Ltd, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Ogeda SA, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Repros Therapeutics Inc, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Richter Gedeon Nyrt, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Dormant Projects, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Uterine Leiomyoma (Uterine Fibroids) Therapeutic Products under Development, Key Players in Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Uterine Leiomyoma (Uterine Fibroids) Pipeline Overview, Uterine Leiomyoma (Uterine Fibroids) Pipeline, Uterine Leiomyoma (Uterine Fibroids) Pipeline Assessment


Companies

AbbVie Inc

Addex Therapeutics Ltd

Auritec Pharmaceuticals Inc

Bayer AG

BioSpecifics Technologies Corp

GeneScience Pharmaceuticals Co Ltd

Immunitor Inc

Kissei Pharmaceutical Co Ltd

Luye Pharma Group Ltd

Ogeda SA

Repros Therapeutics Inc

Richter Gedeon Nyrt

Takeda Pharmaceutical Co Ltd

Uterine Leiomyoma (Uterine Fibroids)-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uterine Leiomyoma (Uterine Fibroids)-Pipeline Review, H2 2018, provides an overview of the Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline landscape.

Uterine fibroids are benign tumors that originate in the uterus (womb). Although they are composed of the same smooth muscle fibers as the uterine wall (myometrium), they are much denser than normal myometrium. Uterine fibroids are usually round. The most common symptoms of uterine fibroids include heavy menstrual bleeding, prolonged menstrual periods seven days or more of menstrual bleeding, pelvic pressure or pain, frequent urination, difficulty emptying bladder, constipation and backache or leg pains.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uterine Leiomyoma (Uterine Fibroids)-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide also reviews of key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 3, 2, 4 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).

- The pipeline guide reviews pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Uterine Leiomyoma (Uterine Fibroids)-Overview

Uterine Leiomyoma (Uterine Fibroids)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Uterine Leiomyoma (Uterine Fibroids)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Uterine Leiomyoma (Uterine Fibroids)-Companies Involved in Therapeutics Development

AbbVie Inc

Addex Therapeutics Ltd

Auritec Pharmaceuticals Inc

Bayer AG

BioSpecifics Technologies Corp

GeneScience Pharmaceuticals Co Ltd

Immunitor Inc

Kissei Pharmaceutical Co Ltd

Luye Pharma Group Ltd

Ogeda SA

Repros Therapeutics Inc

Richter Gedeon Nyrt

Takeda Pharmaceutical Co Ltd

Uterine Leiomyoma (Uterine Fibroids)-Drug Profiles

cetrorelix-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

collagenase clostridium histolyticum-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTX-30916-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Activate Progesterone Receptor for Uterine Fibroids-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EC-313-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elagolix sodium-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fezolinetant-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KLH-2109-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leuprolide acetate SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

relugolix-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

telapristone acetate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

triptorelin acetate ER-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ulipristal acetate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

V-Myoma-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vilaprisan-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPE-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Uterine Leiomyoma (Uterine Fibroids)-Dormant Projects

Uterine Leiomyoma (Uterine Fibroids)-Discontinued Products

Uterine Leiomyoma (Uterine Fibroids)-Product Development Milestones

Featured News & Press Releases

Jul 10, 2018: Myovant Sciences Announces Completion of Screening for Phase 3 LIBERTY 1 Study Evaluating Relugolix in Women with Uterine Fibroids

Jun 29, 2018: CHMP granted a positive opinion for Ulipristal Acetate Gedeon Richter

May 18, 2018: PRAC recommends new measures to minimise risk of rare but serious liver injury with Esmya for fibroids

Apr 27, 2018: AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting

Apr 26, 2018: Allergan to Present New Data at the American College of Obstetrics and Gynecology 67th Annual Clinical and Scientific Meeting 2018

Apr 23, 2018: ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs with its Novel Oral GnRH Receptor Antagonist OBE2109 (KLH-2109)

Mar 15, 2018: Health Canada to conduct review of a new potential safety risk of Fibristal (ulipristal acetate), a medication used to treat fibroids

Mar 13, 2018: AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids

Mar 12, 2018: BioSpecifics Technologies Announces Presentation of Interim Data from Phase 1 Study of CCH for the Treatment of Uterine Fibroids at 65th Annual Scientific Meeting of the Society for Reproductive Investigation

Feb 28, 2018: Allergan Announces FDA Has Extended The Ulipristal Acetate NDA Review Period To August 2018

Feb 21, 2018: AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids

Feb 16, 2018: Esmya: no new treatment courses prescribed until further notice

Feb 09, 2018: Women taking Esmya for uterine fibroids to have regular liver tests while EMA review is ongoing

Dec 01, 2017: EMA starts review of Esmya for uterine fibroids

Nov 09, 2017: Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 Study Evaluating the Efficacy and Safety of Relugolix for the Treatment of Pain Associated with Uterine Fibroids

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by AbbVie Inc, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Addex Therapeutics Ltd, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Auritec Pharmaceuticals Inc, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Bayer AG, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by BioSpecifics Technologies Corp, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Immunitor Inc, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Kissei Pharmaceutical Co Ltd, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Luye Pharma Group Ltd, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Ogeda SA, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Repros Therapeutics Inc, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Richter Gedeon Nyrt, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Dormant Projects, H2 2018

Uterine Leiomyoma (Uterine Fibroids)-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Uterine Leiomyoma (Uterine Fibroids) Therapeutic Products under Development, Key Players in Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Uterine Leiomyoma (Uterine Fibroids) Pipeline Overview, Uterine Leiomyoma (Uterine Fibroids) Pipeline, Uterine Leiomyoma (Uterine Fibroids) Pipeline Assessment


Companies

AbbVie Inc

Addex Therapeutics Ltd

Auritec Pharmaceuticals Inc

Bayer AG

BioSpecifics Technologies Corp

GeneScience Pharmaceuticals Co Ltd

Immunitor Inc

Kissei Pharmaceutical Co Ltd

Luye Pharma Group Ltd

Ogeda SA

Repros Therapeutics Inc

Richter Gedeon Nyrt

Takeda Pharmaceutical Co Ltd